التفاصيل البيبلوغرافية
| العنوان: |
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression. |
| المؤلفون: |
Ainley, Louise1,2 (AUTHOR) louise.ainley@nhs.net, Camilleri, Marquita1,2 (AUTHOR), Chavda, Selina J.1,2 (AUTHOR), McMillan, Annabel1 (AUTHOR), Lee, Lydia1,2 (AUTHOR), Popat, Rakesh1,2 (AUTHOR), Sillito, Francesca1,2 (AUTHOR), Yong, Kwee1,2 (AUTHOR) |
| المصدر: |
British Journal of Haematology. Mar2022, Vol. 196 Issue 6, pe63-e66. 4p. |
| مصطلحات موضوعية: |
*PLASMA cell diseases, *DISEASE progression, *MULTIPLE myeloma, *MONOCLONAL gammopathies |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
A total of 41 (89%) patients started anti-myeloma therapy, three declined, two had not yet commenced treatment; 20 (49%) proceeded to autologous stem cell transplantation (Table SIV). Patients progressing at <6 months from diagnosis were excluded as these patients likely represent evolving disease; similarly those with <6 months of follow-up were also excluded. Smouldering myeloma (SMM) is an asymptomatic stage of multiple myeloma with bone marrow plasma cells >10% or paraprotein >30 g/l, forming a heterogenous group of patients, with variable progression to active myeloma.1 The SMM standard of care is surveillance to identify early progression. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
